D.E. Shaw & Co
RPRX icon

D.E. Shaw & Co’s Royalty Pharma RPRX Stock Holding History

D.E. Shaw & Co’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.4M Sell
525,114
-596,933
-53% -$31.1M 0.01% 1051
2026
Q1 		$53.8M Buy
1,122,047
+283,434
+34% +$12.4M 0.03% 628
2025
Q4 		$32.4M Buy
838,613
+698,585
+499% +$26.6M 0.02% 952
2025
Q3 		$4.94M Buy
140,028
+106,232
+314% +$3.85M ﹤0.01% 2214
2025
Q2 		$1.22M Sell
33,796
-242,043
-88% -$8.02M ﹤0.01% 3099
2025
Q1 		$8.59M Sell
275,839
-885,465
-76% -$28.1M 0.01% 1511
2024
Q4 		$29.6M Buy
1,161,304
+228,964
+25% +$6.07M 0.02% 811
2024
Q3 		$26.4M Buy
932,340
+898,728
+2,674% +$24.9M 0.02% 839
2024
Q2 		$886K Buy
+33,612
New +$932K ﹤0.01% 3270
2024
Q1 		– Sell
-13,387
Closed -$376K – 4673
2023
Q4 		$376K Sell
13,387
-384,459
-97% -$10.6M ﹤0.01% 3653
2023
Q3 		$10.8M Sell
397,846
-28,756
-7% -$854K 0.01% 1243
2023
Q2 		$13.1M Buy
426,602
+96,782
+29% +$3.28M 0.01% 1129
2023
Q1 		$11.9M Sell
329,820
-310,904
-49% -$11.5M 0.01% 1227
2022
Q4 		$25.3M Sell
640,724
-41,062
-6% -$1.71M 0.03% 772
2022
Q3 		$27.4M Buy
681,786
+530,538
+351% +$22.7M 0.03% 675
2022
Q2 		$6.36M Buy
151,248
+69,947
+86% +$2.87M 0.01% 1839
2022
Q1 		$3.17M Buy
+81,301
New +$3.19M ﹤0.01% 2831
2021
Q3 		– Sell
-54,095
Closed -$2.22M – 5190
2021
Q2 		$2.22M Buy
+54,095
New +$2.3M ﹤0.01% 2841

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co's RPRX Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Royalty Pharma (RPRX) stake by 53% in Q2 2026, selling an estimated $31.1M and leaving 525,114 shares worth $29.4M. The position accounts for 0.01% of the portfolio, ranked #1051.

D.E. Shaw & Co first reported a position in RPRX in Q2 2021 and has held it in 18 quarters since. The position peaked at $53.8M in Q1 2026. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • D.E. Shaw & Co held 525,114 shares of Royalty Pharma worth $29.4M as of Q2 2026.
  • D.E. Shaw & Co sold 596,933 Royalty Pharma shares in Q2 2026, an estimated $31.1M.
  • Royalty Pharma made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1051 holding.
  • D.E. Shaw & Co first reported a position in Royalty Pharma in Q2 2021 and has held it in 18 quarters since.
  • D.E. Shaw & Co's Royalty Pharma position peaked at $53.8M in Q1 2026.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.